Kyongbo Pharmaceutical Co., Ltd
KSC: 214390.KS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Korea Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Tae-Young Kim
- Employees
- 505
- Headquarters
- Asan, South Korea
- IPO year
- 2015
- Market cap
- ₩152.3B
- Website
- https://www.kbpharma.co.kr
Loading 214390…
Loading profile data…Frequently asked questions about 214390
What does Kyongbo Pharmaceutical Co., Ltd (214390.KS) do?
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients in South Korea. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also exports its products to 30 countries worldwide. The company was for...
Where does 214390.KS trade?
Kyongbo Pharmaceutical Co., Ltd (214390.KS) trades on the Korea Exchange.
What sector is 214390.KS in?
Kyongbo Pharmaceutical Co., Ltd (214390.KS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Kyongbo Pharmaceutical Co., Ltd?
Tae-Young Kim is the chief executive officer of Kyongbo Pharmaceutical Co., Ltd (214390.KS).
Where is Kyongbo Pharmaceutical Co., Ltd headquartered?
Kyongbo Pharmaceutical Co., Ltd is headquartered in South Korea.
Does 214390.KS pay a dividend?
Yes — Kyongbo Pharmaceutical Co., Ltd (214390.KS) paid a trailing twelve-month dividend of KRW 50.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 214390.KS go public?
Kyongbo Pharmaceutical Co., Ltd (214390.KS) completed its initial public offering in 2015.